Catalyst Event

Regeneron Pharmaceuticals Inc (REGN) · Other

From KEDI Nvidia Fixed Tech100 Index (KNVDT100)

5/28/2026, 12:00:00 AM

OtherSentiment: Positive

Announced on 2026-05-28 that its antibody maftivimab was recommended by the WHO for clinical trial evaluation; expected to have a low impact as an early-stage development milestone.

Korean Translation

2026-05-28, 항체 치료제 마프티비맙의 WHO 임상시험 평가 대상 권고. 초기 개발 단계 성과로 낮은 수준의 영향이 예상됨.

Related Recent Events

View Full Timeline